Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA stays tuned to Taxus adverse events

This article was originally published in The Gray Sheet

Executive Summary

Agency pledges to keep the public apprised of complaints related to the Boston Scientific paclitaxel-eluting stent, but says collected data detailing 28 Taxus incidents to date are insufficient to justify a formal solicitation similar to last October's "web notification" about J&J/Cordis' Cypher thrombosis rates. Some physicians have reported that the Taxus delivery system resists extraction after stent deployment, possibly due to improper balloon deflation. The incident rate is about 11.8 complaints per 1,000 used, Boston Scientific says, attributing the problems to physicians unfamiliar with the system (1"The Gray Sheet" April 26, 2004, p. 5)...

You may also be interested in...

Changes to Taxus manufacturing

FDA approves special PMA supplement May 5 for Boston Scientific to modify the laser bonding process used to unite the drug-eluting stent's delivery catheter and balloon prior to packaging. The move responds to physician complaints about the balloon not deflating properly or sticking to the stent coating during removal (1"The Gray Sheet" May 3, 2004, In Brief). A recall will not be initiated, the company says, claiming the best way to avoid potential problems with existing stents is to follow the instructions for use, specifically concerning inflation and deflation timing and pressure. Boston Scientific attributes the issues to physicians being unfamiliar with the system. FDA does not plan to formally address the issue; however, the agency notes its will provide communications if further problems arise...

Cypher, Taxus Perform Equally Well In Trials, Registries – Meier Analysis

The overall clinical performance of Boston Scientific's Taxus and J&J/Cordis' Cypher drug-eluting coronary stents is practically equivalent, according to Bernard Meier, MD, University Hospital, Bern, Switzerland

Boston Scientific To Study Complex DES Use; Taxus Complaints Surface

Boston Scientific is maintaining a "sober" outlook regarding its chances of obtaining increased reimbursement in the near-term for multi-vessel interventions using drug-eluting stents

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts